Cancer Dx Firm Pillar Biosciences Gets $18M Investment From ORI Healthcare
NEW YORK (GenomeWeb) – Hong Kong-based venture capital group ORI Healthcare Fund announced today that it has made an $18 million investment in Boston-based cancer molecular diagnostics startup Pillar Biosciences.
According to ORI, Pillar is advancing a patent-pending targeted sequencing technology platform and a proprietary data analysis toolkit, which offer high sensitivity and specificity, as well as a fast and affordable method for targeted NGS oncology testing.
The startup has released beta versions of two targeted sequencing panels, one covering somatic mutations associated with lung and colon cancers, and another for BRCA1 and BRCA2 germline mutations. Additional information about beta users of these panels and their content and methodology were not disclosed.
The investment will help Pillar continue its R&D efforts in tissue-based sequencing panels, as well as support efforts to develop new liquid biopsy products, the firm said.
Source: https://www.genomeweb.com/molecular-diagnostics/cancer-dx-firm-pillar-biosciences-gets-18m-investment-ori-healthcare#.Y8jx8nZByUn
Related Posts
Next-Gen Automotive Semiconductors Critical for Level 5 Autonomous Vehicles (June 17, 2025)
Michigan engineers lead hardware innovations to enable AI chips required for full Level 5 autonomous driving. Achieving L5 autonomy demands faster, lower-power, and more durable semiconductors. E-Tronic, a leading Chinese automotive power semiconductor supplier, actively participates in next-gen automotive semiconductor development, supporting autonomous vehicl
Connecting the Future: Web3Labs, IoTeX, and Goldford-HB Ventures Jointly Launch Global Recruitment for DePIN Project
Recently, Asia’s well-known Web3 accelerator Web3Labs officially announced that it will join forces with DePIN infrastructure leader IoTeX and venture capital firm Goldford-HB Ventures to launch a new round of global recruitment for DePIN projects. Committed to finding and cultivating project teams with innovative spirit and strong potential for joint investm
Laekna HK$791 million IPO
We advised Laekna on its IPO and HKEX listing Davis Polk advised Laekna, Inc. in connection with its initial public offering and listing on the Hong Kong Stock Exchange and an international offering in reliance on Regulation S. The net proceeds from the offering amounted to approximately HK$791 million. Founded in 2016, Laekna, Inc. is […]
Leto Laboratories Developing Semaglutide Biosimilar for Diabetes, Currently in Phase II Clinical Trial (2025)
Leto Laboratories is developing a Semaglutide biosimilar for diabetes and weight loss treatment, currently in Phase II clinical trials. The therapeutic candidate targets the GLP-1 receptor. According to GlobalData, Phase II diabetes drugs have a 38% success rate to advance to Phase III. Leto leverages its high-throughput screening and directional protein refold
Leave a Reply